Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib

by Oncoheroes Biosciences

Oncoheroes Biosciences and Novartis have signed a worldwide, exclusive licensing agreement for dovitinib, a multi-tyrosine kinase inhibitor originally developed by Novartis. Under the terms of this ag...

Read more

Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S. FDA

by Oncoheroes Biosciences

Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to dovit...

Read more

FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials

by Oncoheroes Biosciences

Oncoheroes Biosciences, Inc. (“Oncoheroes”) announced today that the U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to proceed with the investigation of two potential...

Read more

Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib

by Oncoheroes Biosciences

Oncoheroes Biosciences, Inc. (“Oncoheroes”), and Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”) have signed a worldwide, exclusive pediatric licensing agreement for dovitinib, a pan-t...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream